New drug aims to stop kidney transplant rejection
Disease control
Not yet recruiting
This study tests a new medicine called CID-103 in adults whose kidney transplants are being rejected by their immune system (antibody-mediated rejection). The trial has two parts: first, to find a safe dose, and second, to see if the drug can stop the rejection. About 58 people w…
Phase: PHASE1, PHASE2 • Sponsor: CASI pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC